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Summary MHC class I antigens are intimately involved in intercellular communication, and recognition by
cytotoxic T cells. Thus tumour cells that fail to express them may be at a growth or metastatic advantage. A
series of ten colorectal and ten breast carcinomas, and their respective lymph node metastases, were examined
immunohistologically using monoclonal antibodies (mAb) against both monomorphic and A2 polymorphic
determinants, and beta-2-microglobulin (beta 2m). Four colon polypoid adenomas and one liver metastasis
were also included in the study. In the colon, all normal tissues and polypoid adenomas stained positively
throughout, but 6/10 primary tumours had partial or complete loss of expression of monomorphic deter-
minants using mAb W6/32: two node and the liver metastasis showed less, four more expression. Similar
results were seen for beta 2m. HLA-A2 expression was absent or reduced in 4/4 colon tumours and all their
metastases. Among the breast tumours, W6/32 staining was absent or reduced in 2/10, and node deposits
showed two with less reactivity than their primary. Beta 2m staining was reduced or absent in 8/10 primaries
and all the node metastases; in every case in which beta 2m was detected in the primary tumour their
corresponding lymph node metastasis showed a decreased expression. HLA-A2 expression was absent or
reduced in 3/4 primary breast carcinomas, and all their metastases. These results show that individual human
colon and breast carcinomas often have a reduced HLA class I antigen expression, which apparently confers a
metastatic advantage.
MHC Class I and II genes encode for proteins which are
intimately involved in intercellular communications, and
establishing self identity for controlling immunological res-
ponses. While MHC class II antigens (in man referred to as
HLA-DR, DP or DQ) have limited expression on cells of the
immune system, MHC Class I antigens are found on all
somatic cells as heterodimeric molecules (Benacerraf, 1981;
Linsk & Goodenow, 1986; Schwartz, 1982). The class I MHC
molecule consists of three alpha regimes, covalently linked
to beta-2-microglobulin (beta 2m), which are encoded by
separate genes, and linked prior to expression at the cell
membrane (Ploegh et al., 1981; Arce-Gomez, 1978). T cell
recognition of antigen at the cell membrane is restricted to
cells expressing compatible HLA determinants (Zinkernagel
& Doherty, 1979). Similarly, immunological recognition of
tumour antigens by cytotoxic T lymphocytes (CTL) is
restricted to histocompatible cell types. Failure to express
HLA class I, or the expression of inappropriate or altered
HLA components on cells, is a possible mechanism whereby
tumour cells may escape destruction by antigen specific CTL.
Several studies have now shown that many human tumours
fail to express antigens recognised by monoclonal antibodies
(mAbs) specific for the monomorphic sites of HLA class I
molecules (Masucci et al., 1987; Smith et al., 1988; 1989;
Broker et al., 1984; Lopez-Nevot et al., 1989; Momburg et
al., 1986; Momburg & Koch, 1989; Muller & Stutte, 1988;
Natali et al., 1983; Perez et al., 1986). Furthermore, some
primary human colon carcinomas fail to express HLA class I
polymorphic regions (Rees et al., 1988; Momburg & Koch,
1989); the absence of these haplotypes may also be signi-
ficant.
Experimental studies in murine tumours have shown that
the expression of H2 D and K products is important, and in
some ways is linked with metastatic potential. With these
immunogenic tumours, those with a high level of MHC
antigen expression show low metastatic ability; transfection
and subsequent expression of the H2K gene into otherwise
highly metastatic H2K-negative tumour cell variants reduces
tumour growth, and prevents metastasis (Eisenbach et al.,
1983; 1984; 1985). Studies on the expression of human MHC
class I antigens in primary vs metastatic tumour are limited;
for example malignant melanoma, digestive tract, and laryn-
geal tumours (Ruiz-Cabello et al., 1989; Esteban et al., 1989).
In these studies, both increased and decreased expression of
monomorphic determinants of HLA class I was observed in
the metastases compared with their primaries. In the present
study we have used mAbs to evaluate a series of human
primary colon and breast carcinomas, and their lymph node
metastases, for the expression of monomorphic and polymor-
phic HLA class I determinants. Normal colon mucosa and,
where possible, colon adenomas and liver metastases were
included in the study. Many of the primary tumours at both
sites showed reduced staining for monomorphic and poly-
morphic HLA class I determinants; metastases showed both
greater and lesser degrees of loss of HLA expression when
compared with their primary.
Materials and methods
Patients, tissue typing and specimen collection
Patients admitted to the study were undergoing surgery for
carcinoma of the breast or large bowel as determined on
clinical grounds. The series represents a collection of cases
made available to the investigators, and is not a consecutive
or other unselected series. The nature of the study dictates
that only cases with node metastases were acceptable, which
means the tumours were relatively advanced, and generally of
high grade malignancy. Patients with colorectal carcinoma
were HLA typed at A and B loci using a standard microlym-
phocytotoxicity assay; breast tumours were typed by
immunostaining for HLA A2. Tissue samples were obtained
from operation specimens for carcinoma of the colon, rec-
tum, or breast. For colorectal specimens samples of tumour,
polypoid adenomas and liver metastasis (if present), normal
colon 5 cm and 15 cm from the tumour, and lymph node
were wrapped in aluminium foil, sprayed with 'Freezit' (Sor-
risol, Merseyside) until frozen, and then stored at - 80°C.
For mastectomies, samples of tumour, normal breast and
lymph node were taken and stored in a similar manner. All
diagnoses were confirmed by conventional paraffin sections
before acceptance into the study.
Immunoperoxidase staining offrozen sections
Cryostat sections were cut at 5-10 microns thickness: spare
sections were stored at - 80°C until used later. After warm-
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ing to room temperature, a standard immunoperoxidase
method was used: 40 microlitre of primary antibody in tris
buffered saline was applied to the sections, and incubated at
4°C overnight. A positive reaction was detected by the
avidin-biotin complex method, with diaminobenzidine as the
final chromogen. All sections contained intrinsic positive and
negative control areas, and negative controls lacking primary
antiserum were also included. The mAbs used as primary
antisera are listed in Table I. All sections were interpreted by
two observers (J.R.G. and L.S.) and equivocal or failed
reactions were repeated. Several patterns of staining were
seen: if all the tumour cells showed membrane staining the
result was expressed as positive ( + ), and if none did it was
negative (-) (only plasma membrane staining was con-
sidered relevant). Partial staining could be a generally faint
reaction (compared with intrinsic control cells), or patchy
positive staining either as part of the specimen, or groups of
cells; this was recorded semi-quantitatively as +/- if more,
or -/+ if less was stained.
Results
MHC class Imonomorphic antigen determinants
A series of ten colonic (or rectal) tumours was obtained. In
nine cases tumour was detected in an adjacent lymph node;
four polypoid adenomas and one liver metastases were also
sampled. Using the mAbs W6/32 (monomorphic backbone
determinants), and anti beta 2m, the pattern of MHC class I
monomorphic antigen expression was assessed. Staining with
the other mAbs (PA2.6 and BBM 1) was generally not so
successful: positive reactions were usually weaker than with
the corresponding other mAb, and there were more failed
and negative reactions; in no instance was there a positive
reaction when the other mAb was negative. For these reasons
the results of staining with PA2.6 and BBM 1 will not be
presented or discussed further.
Table I Monoclonal antibodies to HLA class I
Antibody Specificity Source
W6/32 HLA, A, B, C, Dr Keith Gelsthorpe
monomorphic Sheffield Blood Transfusion Service
(Barnstable et al., 1978)
PA 2.6 HLA, A, B, C Imperial Cancer Research Fund
monomorphic (Brodsky et al., 1979b)
Anti-p2m P2m Sera-Tech Ltd.
Mouse mAb (clone-SLR-2)
BBM.1 P2m Imperial Cancer Research Fund
(Brodsky et al., 1979a)
151-8.1 HLA A2/28 Dr Keith Gelsthorpe
Sheffield Blood Transfusion
Figure 1 Colon primary tumour; partial loss of MHC class I
monomorphic determinants. Positive tumour cells near centre,
majority are negative; stroma is positive (Immunoperoxidase
mAb W6/32).
All normal tissue stained positively with W6/32 and anti
beta 2m mAb, whereas primary tumour was either partly or
wholly negative in six out of ten samples stained with W6/32
(Figure 1), and four out of six stained with anti beta 2m.
Polypoid adenomas were uniformly positive with W6/32 or
anti beta 2m mAb. Two lymph node metastases expressed
less HLA reactivity than their primary tumours (Figure 2),
while four further lymph node metastases had an increased
expression of HLA compared with the primary tumour.
Using anti beta 2m mAb two lymph node metastases showed
a loss of reactivity compared with their primary tumour,
while one metastasis showed an increased expression (Table
II).
Table III shows the results of a similar study using primary
tumour and lymph node metastases from a series of ten
human breast cancers. In these tissues two primary tumours
showed a partial or complete loss of reactivity using W6/32
mAb. Two lymph node metastases had reduced staining with
W6/32 when compared with their primary. A more pro-
nounced loss of reactivity was observed using anti beta 2m
mAb in both primary and lymph node metastases. With the
primary breast carcinomas four tumours showed a complete
absence of anti beta 2m staining, and a further four out of
the ten demonstrated a partial loss of reactivity. The lymph
node metastases showed a complete absence of beta 2m in
eight out of ten tumours: with the remaining two samples
both the primary tumours were uniformly positive, while
their metastases showed only partial expression of beta 2m.
MHC class I HLA A2polymorphic antigen determinants
Eight patients (four colon, four breast carcinomas) were
positive for A2, either on tissue typing or by demonstrating
Table II HLA class I monomorphic antigen expression in primary and metastatic colonic
tumours and polyps
Reactivity with mAb
W6/32 Anti-p2m
Case LN Liver LN Liver
no. Grade" Tumour Met Met Polyp n Tumour Met Met Polyp n
I M _b + + +
2 M - -/+ + + -/+ - + +
3 P -1+ + + + - - + +
4 P +/- + + NT +
5 M + -1+ + NT NT
6 - +/- +/- + + + +
7 M +1- + + +/- + +
8 M + + + + + +
9 M-P + + + + + +
10 W + -/+-/+ + + +/- + - + +
aTumours graded as poor, moderately or well differentiated. bIndicates positive (+),
complete absence (-) or mixed positive and negative ( +/-) staining patterns. NT = not
tested.882 J.R. GOEPEL et al.
a
b
Figur 2 Colon primary a, positive membrane staining; lymph
node metastasis b, negative for MHC class I monomorphic deter-
minants, while stroma (intrinsic control) is positive (Immuno-
peroxidase mAb W6/32).
Table III HLA class I monomorphic antigen expression in primary
breast carcinomas and their nodal metastases
Reactivity with mAb
W6/32 Anti-p2m
Tumour size LN LN
Case (mm) Gradea Tumour Met. Tumour Met.
1 50 p b
2 38 M-P +/- - - -
3 30 P + + - -
4 28 P + + - -
5 38 P + + + +/-
6 28 M + + + -/+
7 30 P + +/- -/+ -
8 30 M + + -/+ -
9 30 p + + +1-
10 16 M + + -/+ -
aTumour graded as poor, moderately, or well differentiated. bIn.
dicates positive ( + ), complete absence (-) or mixed positive and
negative (+/-) staining patterns.
uniformly positive normal tissue; all of the colon and three of
the breast tumours showed partial (Figure 3) or complete
loss of reactivity (Table IV). The lymph nodes from these
breast cancer patients generally had less expression of HLA
A2 antigen; three showed partial, one complete loss of reac-
tivity. Of the four colon tumour samples, three primary
tumours demonstrated a complete absence of HLA A2
antigen, the fourth a partial loss. A similar staining pattern
was observed in the lymph node metastases; a liver metastasis
was negative, whilst the normal mucosa and a polypoid
adenoma were positive.
Figure 3 Breast primary tumour; partial loss of MHC class I
HLA A2 polymorphic determinant (Immunoperoxidase mAb A2/
28).
Table IV Expression of HLA-A2 polymorphic antigen in primary
breast and colon carcinoma and metastasis deposits
A2/28 Monoclonal antibody
Reactivity
Tumour LN Normal
type Case no. Tumour Met. tissue/areas
Breast 7 +/-a -1+ +
carcinomas 8 + +1- +
9 +/- +/- +
10 - -+
Tumour LN Liver Polyp Normal
Met Met.
Colon 7 - NT +
carcinomas 8 -/+ +/- +
9 - - + +
11 - - - + +
aIndicatespositive( + ), completeabsence ( - ) ormixedpositive and
negative (+/-) staining patterns. NT = not tested.
Discussion
The loss or aberrant expression of HLA class I monomorphic
or polymorphic determinants on tumour cells would theore-
tically allow them to escape cytotoxic attack by lymphocytes
mediating antigen specific recognition. Whilst altered expres-
sion has been reported in a wide range of human tumours,
studies to assess this in relation to metastasis are few. Using
mAbs against monomorphic HLA determinants and beta 2m,
examinations of melanoma, squamous carcinoma of larynx,
and colorectal adenocarcinoma have shown divergence and
loss of expression of class I HLA between primary tumours
and their metastases (Esteban et al., 1989; Ruiz-Cabello et
al., 1989). There was also correlation between the grade of
differentiation and expression amongst the laryngeal carcin-
omas, with loss in poorly differentiated tumours. In some
instances the lack of HLA class I expression is due to a loss
of gene activity, as shown in a recent study (Momberg &
Koch, 1989) which demonstrated the absence of beta 2m
protein from human colon carcinomas to be associated with
loss of messenger RNA.
In a previous report we have documented the loss of both
monomorphic and polymorphic HLA class I determinants in
human colon carcinoma (Rees et al., 1988); in several cases
primary tumours that stained with mAb W6/32 failed to
stain with a mAb specific for the appropriate haplotype (A2
or Bw4). The presence study evaluates further the expression
of HLA class I molecules in primary and metastatic deposits
from individual patients with colon or breast carcinoma.
Although partial or total loss of reactivity was observed in
tissue containing tumour, no consistent pattern could be
established between the primary and metastatic tumour in
individual patients. Both an increase and a decrease in HLAHLA ANTIGENS IN METASTATIC CARCINOMA 883
expression was seen in colon carcinoma lymph node deposits
when compared with their primaries; the one liver metastasis
showed a decrease, and the staining of colon polypoid ade-
nomas was identical to normal mucosa. With breast carcin-
omas, although there was some loss of reactivity in the
metastases for HLA class I monomorphic antigen (W6/32
staining), a decrease in staining with anti-beta 2m was seen.
Though this was a striking feature of the breast carcinomas,
it is probably not a true indication of decreased beta 2m, in
view of the non-covalent linkage between it and the rest of
the class I MHC molecule identified by W6/32. Immunohis-
tology is at best only semi-quantitative, and the reduced
staining may reflect a lower affinity for the antibody. The
lack of expression of HLA A2 polymorphic antigen deter-
minants was confirmed in most of the relevant colon car-
cinomas; while some of the breast metastases showed loss
compared with their primaries. Although only eight cases
were examined, these observations provide further evidence
which suggests that loss of class I antigenic determinants is
preferentially associated with metastasis. The cases in this
study have been selected because metastases were available;
the expression of HLA antigens in the primary tumours has
not been compared with its expression in tumours of similar
size and grade without known metastases - features known
to correlate with clinical outcome (and thus metastasis) in
breast carcinoma (Haybittle et al., 1982). In a study by
Ruiz-Cabello et al. (1989), where class I expression was
studied in colon, melanoma and epidermoid tumours, diver-
gence of expression of class I was seen between primary
tumours and their autologous metastases. Of the six cases
reported, only two metastases showed a decrease in the inten-
sity of staining with W6/32 monoclonal antibody compared
with the primary tumour. A further report by this group
(Lopez-Nevot et al., 1989) reported an apparent decrease in
the number of tumour cells expressing monomorphic HLA
antigens in right colon carcinoma metastases.
In colorectal, gastric and laryngeal carcinomas a selective
loss of HLA-B isotype determinants occurred in tumours
previously classified as HLA positive (Lopez-Nevot et al.,
1989). Although differences in HLA expression between
tumour types is observed, a consensus of opinion supports
the view that both monomorphic and polymorphic HLA
determinants are decreased in metastatic tumour deposits
compared with its autologous primary tumour. In spite of
the relationship between HLA expression and immunity, it
may well be that its loss in tumours with an enhanced
metastatic phenotype is a reflection of biological events other
than those of an immunological nature. For example, they
interact with some growth factor receptors and cytoskeletal
proteins, and are capable of modulating secondary and ter-
tiary cell signalling pathways (Haliotis et al., 1990); this may
confer a metastatic advantage.
We wish to thank the Trustees of Weston Park Hospital and the
Yorkshire Cancer Research Campaign for supporting this work.
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